Thanks to the efforts of our AAMDSIF bone marrow failure community and coalition partners, a bipartisan group of 105 U.S. House and 29 Senate members urged their leaders to restore funding to the Congressionally Directed Medical Research Programs (CDMRP) including the Bone Marrow Failure Research Program (BMFRP).
In March, Congress cut funding to the CDMRP by 57% and cut ALL funding to CDMRP’s Bone Marrow Failure Research Program. This means new lifesaving and cutting-edge research through the BMFRP that could lead to treatments for Aplastic Anemia, MDS, PNH, and related bone marrow failure diseases has stopped. This disruption has the potential to negatively impact bone marrow failure research for years to come unless funding is restored and increased.
Due to the bone marrow failure community’s patient, families, and health professionals’ voices and AAMDSIF’s coalition work with the Defense Health Research Consortium (DHRC) the three letters below were sent by a bipartisan group of Representatives and Senators to Congressional leaders.
Please keep calling, writing, and emailing your Members of Congress to restore this essential research funding. You will be able to find the record of our efforts on these Advocacy in Action pages and through email (subscribe here.)
